SEC Filing Summary: Novus Therapeutics, Inc. (10-Q)
Period: Quarter ended June 30, 2017. Issuer discrepancy: The request identifies Eledon Pharmaceuticals, Inc., but the supplied filing is for Novus Therapeutics, Inc. (formerly Tokai Pharmaceuticals). Confirm the intended company and filing before relying on this summary.
Business context and reporting period
Novus was a development-stage specialty pharmaceutical company focused on ear, nose and throat disorders, with no approved products or revenue. On May 9, 2017, it completed a reverse merger with Otic Pharma; the surviving company was renamed Novus, and a one-for-nine reverse stock split followed on May 11. The merger and change in business make reported results difficult to compare directly with 2016.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 2017: $0.533m; 2016: $0.592m | 2017: $1.012m; 2016: $1.282m |
| General and administrative expense | 2017: $6.133m; 2016: $0.340m | 2017: $7.039m; 2016: $0.762m |
| Net loss | 2017: $6.662m; 2016: $1.002m | 2017: $8.036m; 2016: $2.105m |
| Net loss per share | 2017: $1.32; 2016: $2.25 | 2017: $2.51; 2016: $4.68 |
At June 30, cash and cash equivalents were $22.498m; working capital was $21.7m; total liabilities were $3.405m; and accumulated deficit was $22.426m. The company had no convertible debt outstanding: $3.447m of notes and interest converted to common stock in connection with the merger. Net cash used in operating activities was $8.913m in the first half, versus $2.162m in 2016. Cash and cash equivalents plus restricted cash at period-end totaled $22.581m. The company reported no material interest-rate exposure, but held cash at financial institutions in excess of federally insured limits.
Margins are not meaningful because the company had no revenue. The reported loss-per-share comparisons are also affected by the merger and retroactive reverse-split presentation.
Material changes and unusual items
- G&A expense rose sharply, primarily reflecting merger and public-company costs, including severance: $5.4m recognized in the quarter and $7.0m in the first half. Aggregate merger transaction costs were $7.7m.
- Cash increased mainly from $23.25m received in the merger, $4.0m in private-placement proceeds and $3.119m from warrant exercises; these inflows offset operating cash use.
- R&D expense declined year over year as OP-01 spending decreased, partly offset by OP-02 formulation work and legacy-program costs.
- Reported first-half results include the merger-period effects; pro forma results in the filing are estimates and are not necessarily indicative of actual combined results.
Outlook, risks and contingencies
After the merger, Novus paused OP-01 development and focused substantially all resources on OP-02, a proposed nasal surfactant treatment for otitis media. OP-02 had not yet been made in a cGMP batch suitable for clinical trials. Subject to successful formulation development and manufacturing, management expected to begin a Phase 1 study in 2018; later-stage trials were planned, not assured. Management expected available cash to fund operations for at least 12 months from issuance of the financial statements, while anticipating continued losses and possible need for additional financing.
Key risks include clinical, manufacturing and regulatory failure or delay; the need for additional capital and potential shareholder dilution; reliance on third-party suppliers; intellectual-property and licensing risks; and the possibility that products never reach commercialization. The filing describes several securities class actions related to Tokai’s clinical trials and IPO, plus merger-related stockholder litigation. Two merger-related plaintiffs dismissed their claims with prejudice as to themselves, but without prejudice as to the putative class. The company said it could not estimate potential losses or their range; an unfavorable outcome could materially affect results or cash flows. No contingent liabilities requiring accrual were reported at June 30. Disclosure controls were assessed as effective; financial-reporting processes were being integrated following the merger.
Most important facts for investors to verify
- Confirm that the Novus filing, rather than an Eledon filing, is the intended document.
- Verify post-merger cash runway against actual operating burn and planned OP-02 formulation, manufacturing and clinical spending.
- Track whether OP-02 achieves cGMP manufacturing readiness and whether the anticipated 2018 Phase 1 start remains feasible.
- Assess the status and potential financial exposure of the pending securities litigation.
- Review dilution, share-count effects and any additional financing needs, considering the reverse merger, private placement, warrant exercises and reverse split.